# Safety and Efficacy of CG53135-05 in the Prevention of Oral Mucositis in Patients Receiving Bone Marrow Transplant

> **NCT00104065** · PHASE2 · COMPLETED · sponsor: **CuraGen Corporation**

## Conditions studied

- Stomatitis

## Interventions

- **DRUG:** CG53135-05, velafermin

## Key facts

- **NCT ID:** NCT00104065
- **Lead sponsor:** CuraGen Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-01
- **Primary completion:** 2005-12
- **Final completion:** 2005-12
- **Target enrollment:** — (—)
- **Last updated:** 2016-03-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00104065

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00104065, "Safety and Efficacy of CG53135-05 in the Prevention of Oral Mucositis in Patients Receiving Bone Marrow Transplant". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00104065. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*